

Michael C Haffner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7568562/publications.pdf>

Version: 2024-02-01

61
papers

3,223
citations

270111

25
h-index

182931

54
g-index

63
all docs

63
docs citations

63
times ranked

5536
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. <i>Oncogene</i> , 2022, , .	2.6	6
2	Whole Genome Sequencing Reveals Independent Clonal Origin of Bilateral Testicular Germ Cell Tumors in Two Patients with Pure Seminoma. <i>Urology</i> , 2022, , .	0.5	0
3	Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes. <i>Cell Reports Medicine</i> , 2022, 3, 100493.	3.3	3
4	SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples. <i>Clinical Epigenetics</i> , 2022, 14, 37.	1.8	3
5	Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations. <i>Cancer Research Communications</i> , 2022, 2, 277-285.	0.7	4
6	Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole-Genome Sequencing. <i>Molecular Cancer Research</i> , 2022, 20, 1013-1020.	1.5	3
7	Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3127-3140.	3.2	11
8	Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3509-3525.	3.2	11
9	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5â€“SN38 Antibodyâ€“drug Conjugate in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 759-774.	3.2	34
10	Genomic and phenotypic heterogeneity in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 79-92.	1.9	215
11	Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases. <i>Molecular Oncology</i> , 2021, 15, 1942-1955.	2.1	10
12	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	22
13	Downregulation of 5â€“hydroxymethylcytosine is an early event in pancreatic tumorigenesis. <i>Journal of Pathology</i> , 2021, 254, 279-288.	2.1	12
14	TGM4: an immunogenic prostate-restricted antigen. , 2021, 9, e001649.		11
15	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4736-4750.	0.4	18
16	Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. <i>Nature Cancer</i> , 2021, 2, 803-818.	5.7	54
17	Phenotypic characterization of two novel cell line models of castrationâ€“resistant prostate cancer. <i>Prostate</i> , 2021, 81, 1159-1171.	1.2	9
18	Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18

#	ARTICLE	IF	CITATIONS
19	Molecular Pathology of Prostate Cancer. <i>Surgical Pathology Clinics</i> , 2021, 14, 387-401.	0.7	9
20	Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology</i> , 2021, 80, 573-574.	0.9	1
21	Reciprocal <i>YAP1</i> loss and <i>INSM1</i> expression in neuroendocrine prostate cancer. <i>Journal of Pathology</i> , 2021, 255, 425-437.	2.1	12
22	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 5775.	5.8	59
23	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1167-1179.	1.5	28
24	Putative Autoantigen Leiomodin-1 Is Expressed in the Human Brain and in the Membrane Fraction of Newly Formed Neurons. <i>Pathogens</i> , 2020, 9, 1036.	1.2	11
25	Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 847-861.	2.1	14
26	A Comprehensive Analysis of FUT8 Overexpressing Prostate Cancer Cells Reveals the Role of EGFR in Castration Resistance. <i>Cancers</i> , 2020, 12, 468.	1.7	25
27	Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort. <i>Human Pathology</i> , 2020, 98, 74-80.	1.1	21
28	An in Situ Atlas of Mitochondrial DNA in Mammalian Tissues Reveals High Content in Stem and Proliferative Compartments. <i>American Journal of Pathology</i> , 2020, 190, 1565-1579.	1.9	21
29	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. <i>Human Pathology</i> , 2020, 101, 70-79.	1.1	5
30	Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030403.	2.9	25
31	Functional Loss of <i>ATR</i> and <i>TERC</i> Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2019, 17, 2480-2491.	1.5	25
32	Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. <i>American Journal of Pathology</i> , 2019, 189, 2311-2322.	1.9	13
33	Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. <i>Cancer Research</i> , 2019, 79, 3636-3650.	0.4	47
34	If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease. <i>Asian Journal of Urology</i> , 2019, 6, 10-25.	0.5	20
35	Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?. <i>European Urology</i> , 2019, 75, 42-43.	0.9	1
36	Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 137-146.	2.0	35

#	ARTICLE	IF	CITATIONS
37	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	1.9	119
38	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018, 9, 28561-28571.	0.8	129
39	Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. <i>Nature Communications</i> , 2018, 9, 5410.	5.8	30
40	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4693-4703.	3.2	62
41	AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. <i>Nature Communications</i> , 2017, 8, 142.	5.8	36
42	Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4651-4663.	3.2	34
43	Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. <i>Journal of Pathology</i> , 2016, 238, 31-41.	2.1	83
44	Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia. <i>European Urology</i> , 2016, 69, 831-833.	0.9	8
45	Premalignancy in Prostate Cancer: Rethinking What We Know. <i>Cancer Prevention Research</i> , 2016, 9, 648-656.	0.7	44
46	Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. <i>Clinical Cancer Research</i> , 2016, 22, 3310-3319.	3.2	37
47	Diagnostic Challenges of Clonal Heterogeneity in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e38-e40.	0.8	48
48	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	5.8	205
49	Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. <i>Modern Pathology</i> , 2015, 28, 446-456.	2.9	49
50	Combining routine morphology, p16INK4a immunohistochemistry, and in situ hybridization for the detection of human papillomavirus infection in penile carcinomas: A tissue microarray study using classifier performance analyses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 171-177.	0.8	32
51	Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease. <i>Cell Cycle</i> , 2013, 12, 1835-1841.	1.3	23
52	High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. <i>Modern Pathology</i> , 2012, 25, 1079-1085.	2.9	69
53	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. <i>Oncotarget</i> , 2011, 2, 627-637.	0.8	383
54	Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?. <i>Clinical Cancer Research</i> , 2011, 17, 3858-3864.	3.2	92

#	ARTICLE	IF	CITATIONS
55	Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. <i>Nature Genetics</i> , 2010, 42, 668-675.	9.4	539
56	Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. <i>Human Pathology</i> , 2009, 40, 1754-1761.	1.1	209
57	Interaction and Functional Interference of Glucocorticoid Receptor and SOCS1. <i>Journal of Biological Chemistry</i> , 2008, 283, 22089-22096.	1.6	33
58	Insulin-Like Growth Factor-Binding Protein-5 Enters Vesicular Structures but Not the Nucleus. <i>Traffic</i> , 2007, 8, 1815-1828.	1.3	23
59	Favorable prognostic value of SOCS2 and IGF-I in breast cancer. <i>BMC Cancer</i> , 2007, 7, 136.	1.1	55
60	Exploiting Our Knowledge of NF- κ B Signaling for the Treatment of Mammary Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2006, 11, 63-73.	1.0	40
61	Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: Impact of neurovascular bundle preservation. <i>Urology</i> , 2005, 66, 371-376.	0.5	24